CN115427055A - IFN-γ在制备抗肿瘤辅助药物中的应用 - Google Patents
IFN-γ在制备抗肿瘤辅助药物中的应用 Download PDFInfo
- Publication number
- CN115427055A CN115427055A CN202180019514.XA CN202180019514A CN115427055A CN 115427055 A CN115427055 A CN 115427055A CN 202180019514 A CN202180019514 A CN 202180019514A CN 115427055 A CN115427055 A CN 115427055A
- Authority
- CN
- China
- Prior art keywords
- ifn
- tumor
- car
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010074328 Interferon-gamma Proteins 0.000 title claims abstract description 140
- 102100037850 Interferon gamma Human genes 0.000 title claims abstract description 136
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 76
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 203
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 121
- 230000002147 killing effect Effects 0.000 claims abstract description 56
- 238000009169 immunotherapy Methods 0.000 claims abstract description 29
- 239000012634 fragment Substances 0.000 claims abstract description 17
- 238000010353 genetic engineering Methods 0.000 claims abstract description 17
- 230000001235 sensitizing effect Effects 0.000 claims abstract description 16
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 238000012239 gene modification Methods 0.000 claims abstract description 5
- 230000005017 genetic modification Effects 0.000 claims abstract 2
- 235000013617 genetically modified food Nutrition 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 165
- 206010028980 Neoplasm Diseases 0.000 claims description 107
- 230000000694 effects Effects 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 42
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 31
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 31
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 31
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 29
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 28
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 28
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 28
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 27
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 25
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 25
- 239000013604 expression vector Substances 0.000 claims description 24
- 230000019491 signal transduction Effects 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 15
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 15
- 206010005003 Bladder cancer Diseases 0.000 claims description 14
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 14
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 14
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 13
- 229940041181 antineoplastic drug Drugs 0.000 claims description 13
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 13
- 201000007983 brain glioma Diseases 0.000 claims description 12
- 229960003301 nivolumab Drugs 0.000 claims description 11
- 229960002621 pembrolizumab Drugs 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 229960003852 atezolizumab Drugs 0.000 claims description 9
- 229950002916 avelumab Drugs 0.000 claims description 9
- 229950009791 durvalumab Drugs 0.000 claims description 9
- 102000003735 Mesothelin Human genes 0.000 claims description 8
- 108090000015 Mesothelin Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 229950007712 camrelizumab Drugs 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 229940121497 sintilimab Drugs 0.000 claims description 8
- 229950007123 tislelizumab Drugs 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 7
- 241000713666 Lentivirus Species 0.000 claims description 6
- 230000000139 costimulatory effect Effects 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000003827 upregulation Effects 0.000 claims description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- -1 GPC-3 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 3
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 102100040120 Prominin-1 Human genes 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 3
- 229940127086 antineoplastic adjuvant Drugs 0.000 claims 3
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 52
- 108010074708 B7-H1 Antigen Proteins 0.000 description 52
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 34
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 34
- 238000011282 treatment Methods 0.000 description 26
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000004048 modification Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000002708 enhancing effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000011467 adoptive cell therapy Methods 0.000 description 6
- 238000011398 antitumor immunotherapy Methods 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000002619 cancer immunotherapy Methods 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011357 CAR T-cell therapy Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 230000005909 tumor killing Effects 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 229940121420 cemiplimab Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 230000033540 T cell apoptotic process Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 238000003568 cytokine secretion assay Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003370 receptor cell Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 101150049909 R2 gene Proteins 0.000 description 1
- 229940046176 T-cell checkpoint inhibitor Drugs 0.000 description 1
- 239000012644 T-cell checkpoint inhibitor Substances 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了IFN‑γ在制备抗肿瘤辅助药物中的应用，所述IFN‑γ通过致敏肿瘤细胞增强所述T细胞制剂对所述肿瘤细胞的杀伤效果；所述T细胞制剂包括无基因修饰的T细胞和/或用基因工程手段修饰的T细胞；所述IFN‑γ包括野生型或突变的IFN‑γ全长或IFN‑γ片段。本发明突破了现有技术中对IFN‑γ的认知，发现IFN‑γ通过活化肿瘤细胞中IFN‑γ信号通路，抑制了PD‑L1‑PD‑1介导的获得性免疫抵抗，增强免疫治疗的抗肿瘤作用。
Description
PCT国内申请，说明书已公开。
Claims (43)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010159630.9A CN113368217B (zh) | 2020-03-09 | 2020-03-09 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
| CN2020101596309 | 2020-03-09 | ||
| CN2020104871100 | 2020-06-01 | ||
| CN202010487110 | 2020-06-01 | ||
| PCT/CN2021/078858 WO2021179967A1 (zh) | 2020-03-09 | 2021-03-03 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115427055A true CN115427055A (zh) | 2022-12-02 |
Family
ID=77671230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180019514.XA Pending CN115427055A (zh) | 2020-03-09 | 2021-03-03 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230310548A1 (zh) |
| EP (1) | EP4119152A1 (zh) |
| JP (1) | JP2023517599A (zh) |
| CN (1) | CN115427055A (zh) |
| AU (1) | AU2021234454A1 (zh) |
| WO (1) | WO2021179967A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368217A (zh) * | 2020-03-09 | 2021-09-10 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117242090A (zh) * | 2021-03-30 | 2023-12-15 | 希望之城公司 | CAR T细胞疗法和IFNγ |
| CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296421A (zh) * | 2015-11-24 | 2016-02-03 | 高岱清 | 一种双特异性抗体活化的t细胞及制备方法与应用 |
| WO2018103734A1 (zh) * | 2016-12-09 | 2018-06-14 | 北京中捭生物科技有限公司 | 嵌合抗原受体及其用途和制备方法 |
| CN108753773A (zh) * | 2018-05-03 | 2018-11-06 | 山东省齐鲁细胞治疗工程技术有限公司 | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 |
| WO2019020089A1 (zh) * | 2017-07-27 | 2019-01-31 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| WO2019154204A1 (zh) * | 2018-02-09 | 2019-08-15 | 上海交通大学医学院附属上海儿童医学中心 | 一种嵌合抗原受体基因工程载体、修饰的免疫细胞及其应用 |
| CN110305906A (zh) * | 2019-07-18 | 2019-10-08 | 山东大学第二医院 | 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞 |
| WO2020042647A1 (zh) * | 2018-08-28 | 2020-03-05 | 北京永泰瑞科生物科技有限公司 | 改进的治疗性t细胞 |
-
2021
- 2021-03-03 JP JP2022554580A patent/JP2023517599A/ja active Pending
- 2021-03-03 AU AU2021234454A patent/AU2021234454A1/en active Pending
- 2021-03-03 CN CN202180019514.XA patent/CN115427055A/zh active Pending
- 2021-03-03 WO PCT/CN2021/078858 patent/WO2021179967A1/zh unknown
- 2021-03-03 EP EP21767693.1A patent/EP4119152A1/en active Pending
- 2021-03-03 US US17/910,310 patent/US20230310548A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296421A (zh) * | 2015-11-24 | 2016-02-03 | 高岱清 | 一种双特异性抗体活化的t细胞及制备方法与应用 |
| WO2018103734A1 (zh) * | 2016-12-09 | 2018-06-14 | 北京中捭生物科技有限公司 | 嵌合抗原受体及其用途和制备方法 |
| WO2019020089A1 (zh) * | 2017-07-27 | 2019-01-31 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| WO2019154204A1 (zh) * | 2018-02-09 | 2019-08-15 | 上海交通大学医学院附属上海儿童医学中心 | 一种嵌合抗原受体基因工程载体、修饰的免疫细胞及其应用 |
| CN108753773A (zh) * | 2018-05-03 | 2018-11-06 | 山东省齐鲁细胞治疗工程技术有限公司 | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 |
| WO2020042647A1 (zh) * | 2018-08-28 | 2020-03-05 | 北京永泰瑞科生物科技有限公司 | 改进的治疗性t细胞 |
| CN110305906A (zh) * | 2019-07-18 | 2019-10-08 | 山东大学第二医院 | 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞 |
Non-Patent Citations (3)
| Title |
|---|
| YU YANG NG: "T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication", 《MOLECULAR THERAPY》, vol. 29, 1 January 2020 (2020-01-01), pages 75 - 85, XP055963193, DOI: 10.1016/j.ymthe.2020.08.016 * |
| 李充璧: "《分子免疫学原理与技术》", 30 June 2016, 科学技术文献出版社, pages: 228 * |
| 李永强: "靶向HER2的CAR-T细胞构建与抗肿瘤活性的体外分析", 《生物工程学报》, vol. 34, no. 5, 25 May 2018 (2018-05-25), pages 731 - 742 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113368217A (zh) * | 2020-03-09 | 2021-09-10 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
| CN113368217B (zh) * | 2020-03-09 | 2024-02-27 | 四川大学华西医院 | IFN-γ在制备抗肿瘤辅助药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023517599A (ja) | 2023-04-26 |
| US20230310548A1 (en) | 2023-10-05 |
| EP4119152A1 (en) | 2023-01-18 |
| WO2021179967A1 (zh) | 2021-09-16 |
| AU2021234454A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Guo et al. | Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity | |
| Barsoumian et al. | Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma | |
| Cummins et al. | Treating relapsed/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells | |
| Osipov et al. | From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy | |
| Kim et al. | Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model | |
| Li et al. | CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency | |
| Chen et al. | A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases | |
| CN115427055A (zh) | IFN-γ在制备抗肿瘤辅助药物中的应用 | |
| Morimoto et al. | Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells | |
| Ge et al. | Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety | |
| TW201827455A (zh) | 用於治療癌症之表現膜錨定il-12之t細胞 | |
| EP3778649A1 (en) | Method and composition for treating tumors | |
| US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
| CN110520438A (zh) | 溶瘤病毒疗法 | |
| Zhao et al. | An optogenetic controllable T cell system for hepatocellular carcinoma immunotherapy | |
| Chang et al. | Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity | |
| Afolabi et al. | Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat | |
| Sanghera et al. | Immunotherapy–strategies for expanding its role in the treatment of all major tumor sites | |
| CN113368217B (zh) | IFN-γ在制备抗肿瘤辅助药物中的应用 | |
| Ma et al. | EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma | |
| Shang et al. | Gene silencing of indoleamine 2, 3‑dioxygenase 1 inhibits lung cancer growth by suppressing T‑cell exhaustion | |
| Wang et al. | Breakthrough of solid tumor treatment: CAR-NK immunotherapy | |
| CN114588255A (zh) | 基于mRNA的肿瘤疫苗及其制备和联合抗癌方法 | |
| CN116554357A (zh) | 一种双特异性嵌合抗原受体（car）及其在制备抗肿瘤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |